DNA Biomedical Solutions Ltd.: Entera’s unsuccessful NASDAQ IPO is not expected to have a significant impact on its clinical plans; Price target affected by a change in the exchange rate.

• jaimeuss_admin
• 6 בSeptember 2018
• Research
• 0 Comments

Continue Reading